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Abstract:  
This study aimed to investigate the possible presence of BRAF V600E mutation in the Iraqi female 
patients who diagnosed with breast cancer in different ages, in which Blood and tissue samples were 
collected from 46 female patients with  age (46.73±3.54);Those were divided into two groups; who took 
chemotherapy (31 persons) as treated group and without chemotherapy as an untreated group (15 persons) 
and from (23) healthy person with age(47.93±3.05).  Polymerase chain reaction (PCR) were done with 
newly designed primers. The results revealed no correlation between breast cancer occurrence and BRAF 
V600E mutation in the Iraqi patients enrolled  in the current study.   
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ةصلاخلا  
 ةرفط دوجو نع يرحتلا ىلا ةساردلا هذه تفدهBRAF V600Eباصلااب نهصيخشت مت يتلا ثانلاا يف اهمدع نم  يدثلا ناطرسب ة
ةفلتخم رامعا يفوت ثيح ،انيع عمج م نم ةجسنلااو مدلا ت٤٦ رامعابو ةضيرم)٤٦± ٣,٥٤( ،نيتعومجم ىللا اهميسقت مت ثيح ،ةعومجملا 
 اهددعو يوايميكلا جلاعلا تحت  يتلا٣١ اهددعو يوايميك جلاع نودب ىرخلاا ةعومجملاو ةباصم ١٥ عم جئاتنلا ةنراقم مت امك ةباصم 
 مهددعو ةرطيس ةعومجمك ءاحصلاا ةعومجم٢٣رامعابو اصخش )٤٧,٩٣±٣,٠٥ (ةنس. لسلستملا ةرملبلا لعافت  ءارجا مت) (PCR 
تانيعلا عيمج ىلع ةيلاحلا ةساردلا نمض اهميمصت مت ئداوب مادختسابو . يدثلا ناطرسب ةباصلاا نيبام ةقلاع دوجو مدع جئاتنلا ترهظا
 ةرفطوBRAF V600Eةيلاحلا ةساردلاب نيلومشملا نيقارعلا ىضرملا يف .  
فملا تاملكلااتةيح: يدثلا ناطرس  ، ةرفط ،قارعلا  
Introduction  
Breast cancer is the mainly diagnosed malignant tumor of women in a lot of 
countries (Zekri, Bahnassy et al., 2012).In Iraq and other Arab countries, breast cancer 
comes first among other malignancies (Najjar and Easson 2010; Al-Hashimi and Wang 
2014). Breast cancer incidence represented about 34 % of the total cancer cases among 
females from (2000-2009) registered in Iraq (Al-Hashimi and Wang,2014). 
The gene BRAF is a “serine/threonine protein kinase, encoded on chromosome 
7q34” that initiates the MAP kinase/ERK-signaling pathway(Cui et al.,2010). Raf kinases 
(A-Raf, B-Raf, and C-Raf) arouse the mitogen-activated protein kinase (MAPK) cascade, 
which composed of mitogen-activated protein/extracellular signal–regulated kinase 
(MEK) and extracellular-signal regulated kinase (ERK).As the three Raf kinase members, 
B-Raf is the most strong MEK activator with major roles in cell development, cell cycle 
progression, and survival(Manousaridis and Mavridou et al.,2013; Favre,2014) and is 
frequently deregulated in cancer(Wong,2009). Activation of Ras/Raf/MEK/ERK pathway 
is found in more than 25% human cancers(Zhang et al.,2016). 
The BRAF gene is regularly active in the mitogen-activated protein kinase/ 
extracellular signal-regulated kinase signaling pathway which has an effect on  cell 
growth  and differentiation(Wang et al.,2015).Malignant tumors arise through the 
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gathering of epigenetic and genetic alternations (Kikuchi et al.,2013). V600E mutation of 
BRAF that alters the encoded amino acid from valine to glutamic acid at the position 600 
(Janku et al., 2012),Association of BRAF mutation with many kinds of cancer have been 
studied (Millington,2013) neck cancer (Kikuchi et al., 2013), thyroid cancer (Kikuchi et 
al., 2013),lung cancer (Goldman and Gray,2015) and breast cancer (Kim et al.,2013). 
In last years , the study of the molecular pathways of breast cancer  has shown  that 
the BRAF gene mutation is an important event in the process of this disease(Wang et al., 
2015). The V600E mutation of the BRAF gene was noticed in lung cancer(Ueda et al., 
2008; Ohba et al.,2015),central nervous system neoplasms (Behling et al.,2016), papillary 
thyroid carcinoma (Kim et al., 2016), colorectal cancer (Sueda et al.,2016) .in breast 
cancer in which some studies showed the absence the mutations (Barras et al.,2016) 
while the other proved the presence of the mutation (Davies, et al. 2002; Jung et al., 
2016).So it was questionable issue in the field of molecular biology of cancer. 
 
Materials and methods  
Blood samples were collected from (23) healthy person with age (47.93±3.05). 
Blood and tissue samples were collected from 46 female patients with age (46.73±3.54). 
Those also divided into two groups those were taken therapy (31 persons) as treated 
group and those without therapy as an untreated group (15 persons) .The patients and 
healthy groups are matched in age. Five milliliters of venous blood samples were 
collected in Na-EDTA tubes. The serum and whole blood kept frozen at (-20°C) until 
further application in  different assays and DNA extraction was done by  genomic DNA 
extraction blood kit  from (Favorgen, South Korea). The extracted DNA was stored at -20 
  C. mutant primers were designed as shown in table (1) , these Oligonucleotides used in 
this study were designed based on BRAF V600E sequence in NCBI database and these 
primers have been  synthesized by (Bioneer, South Korea). Polymerase chain reactions 
(PCR) were conducted using the AccuPower PCR premix with the thermal cycler 
LABNET (USA), the reaction conditions were as follows: initial denaturation step at 
94°C/5 min followed by 40 cycles; consisting of denaturation step at 94 °C/30 s, 
annealing step at 60 °C/60 s, and extension step at 72 °C/ 50 s with a final extension step 
at 72 °C/5 min. The PCR products were analyzed by 1.5 % agarose gel electrophoresis 
containing 0.5 µg/ml Ethidium bromide and visualized under ultraviolet light for 
detection of amplified DAN bands. 
Table(1): PCR Oligonucleotides used to detect BRAF V600E mutation 
Primers Sequence Amplicon length 
BRAF Forward 5'TCCTAACACATTTCAAGCCCCA3' 
BRAF Reverse (Mutant) 5'GACCCACTCCATCGAGATTTCT 3' 
312 bp 
 
Results  
BRAF is the family member most strongly activated by Ras (Ascierto et al., 2012). 
BRAF is a serine/threonine protein kinase(Wong,2009). The correlation between the 
BRAF V600E mutation and breast cancer is unresolved, according to previous studies; 
some researchers showed that there may be a possible role of that mutation in the breast 
cancer, while the others found no clear correlation. 
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Figure (1): Electrophoresis pattern of PCR for detection of BRAF mutation, lanes 
No 1-8) refer to breast cancer patients samples, lanes(9-16) refer to healthy 
individuals sample. M: Refer to (100bp DNA Ladder). Agarose 1.5% with 5v/Cm. 
 
Blood samples were collected from forty-six female patients age (46.73±3.54, mean 
± SD) and Twenty-three healthy persons age(47.93±3.05, mean ± SD) and PCR assays 
were conducted using PCR reaction in which it was repeated three times to confirm the 
final results, the results revealed no BRAF V600E mutations were detected in the 
examined samples as shown in figure (1). 
 
Discussion 
In Melanoma, about 50% has BRAF mutation with 90% of them as V600E 
mutations(Ascierto et al.,2012).BRAF V600E mutation was recognized in 13.4% of 
colorectal cancer(Vandrovcova et al.,2006). 
The correlation between BRAF V600E mutation and different types of cancer was 
controversial through previous studies; Zeng et al.(2016) showed that Hashimoto's 
thyroiditis was not clearly associated with BRAF(V600E) mutation I which Hashimoto's 
thyroiditis was negatively associated with BRAF(V600E) mutation. In differentiated 
thyroid cancer (DTC),BRAF(V600E) was not considerably associated with( CLNM) 
central lymph node metastases(Han et al., 2016). 
The results of the current study showed the lack of BRAF V600E mutation in the 
patients who diagnosed with breast cancer in Iraq , these findings are similar to results of 
Myers et al.(Myers et al.,2016) in which he indicated the rare presence of  BRAF V600 
mutation in the breast cancer patients which suggests other  molecular causes behind the 
breast cancer  occurance in pateints enroled in the current study, although The RAS–
RAF–MEK–ERK kinase protein path play important roles in  cellular responses to 
growth signals(Davies et al.,2002). Mutations in this signals chains are frequently noticed 
in altered cell lines and commonly linked with human cancers (Chang et al.,2003).RAS is 
mutated to an oncogenic form in more than 14% of human cancer (Davies et al.,2002). 
There are three Raf kinases-A-Raf, B-Raf, and C-Raf; only B-Raf is generally mutated in 
a many type of cancers in which it may bear a resemblance to the meiosis process in the 
M     1       2       3        4          5        6      7      8        M      ٩     ١٠    ١١      ١٢      ١٣      ١٤    ١٥     
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normal cells (Wong,2009). B-Raf is the most widespread mutation type which is based on 
a substitution of a Glutamic acid residue to a Valine residue at codon #600(Cui et al. 
2010). Germ cells mutations in a number of members of RAS/RAF/MEK/ERK pathway 
cause genetic disorders (Tumurkhuu et al.,2010). In the direction of treatment of  some 
types of cancer; the Ras/Raf/MEK/ERK pathway can be activated by chemotherapeutic 
drugs usually used in leukemia treatment through controlling the level of protein 
expression of that pathway(Steelman et al.,2011)and in treatment of Melanoma 
(Favre,2014).  
The Ras/Raf/MEK/ERK pathway has an important  role in osteosarcoma lung 
metastasis (Yu et al.,2011). 
 
Conclusions  
In this study, we concluded that there is no obvious correlation between breast 
cancer occurrence and BRAF V600E mutation in the Iraqi patients who participated in 
the current study. 
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